文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

1型糖尿病与代谢相关脂肪性肝病之间的病理生理联系:对胰岛素抵抗和肝功能障碍的见解

The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction.

作者信息

Herrera-Ojeda José L, Blanco-Palma Ray S, Chávez-Tapia Norberto C, Uribe Misael, Montalvo-Javé Eduardo E, Nuño-Lámbarri Natalia

机构信息

Traslational Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico.

Department of Surgery Faculty of Medicine, The National Autonomous University of Mexico (UNAM), Mexico City, Mexico.

出版信息

J Endocrinol Invest. 2025 Jun 27. doi: 10.1007/s40618-025-02621-5.


DOI:10.1007/s40618-025-02621-5
PMID:40576926
Abstract

Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder characterized by the destruction of pancreatic β-cells, leading to significant endogenous insulin deficiency. In this context, inflammation plays a crucial role in the pathogenesis of the disease. Traditionally, insulin resistance has been associated with Type 2 Diabetes Mellitus (T2DM); however, recent studies have shown that it also occurs in a significant proportion of T1DM patients. Regarding the prevalence of Non-Alcoholic Fatty Liver Disease associated with metabolic dysfunction (MASLD), variations are observed depending on the studied population and diagnostic method used, although there has been a global increase in this condition in T1DM patients. MASLD is closely linked to insulin resistance, both hepatic and peripheral, suggesting that MASLD progression is associated with worsening insulin resistance. The relationship between both pathologies is bidirectional, as the presence of one can accelerate the progression of the other. When both coexist, the natural history of both diseases is altered, increasing the risk of complications and worsening patient prognosis.

摘要

1型糖尿病(T1DM)是一种自身免疫性疾病,其特征是胰腺β细胞被破坏,导致严重的内源性胰岛素缺乏。在这种情况下,炎症在该疾病的发病机制中起关键作用。传统上,胰岛素抵抗与2型糖尿病(T2DM)相关;然而,最近的研究表明,它也在相当比例的T1DM患者中出现。关于与代谢功能障碍相关的非酒精性脂肪性肝病(MASLD)的患病率,尽管T1DM患者中这种情况在全球范围内有所增加,但根据所研究的人群和使用的诊断方法会观察到差异。MASLD与肝脏和外周的胰岛素抵抗密切相关,这表明MASLD的进展与胰岛素抵抗的恶化有关。两种病理之间的关系是双向的,因为一种疾病的存在会加速另一种疾病的进展。当两者共存时,两种疾病的自然病程会改变,增加并发症的风险并恶化患者的预后。

相似文献

[1]
The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction.

J Endocrinol Invest. 2025-6-27

[2]
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.

World J Gastroenterol. 2025-5-28

[3]
MASLD Complicated By Diabetes: Pathophysiology and Emerging Therapies.

J Obes Metab Syndr. 2025-6-20

[4]
Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review.

J Manag Care Pharm. 2012-8

[5]
The Changing Epidemiology of Type 1 Diabetes: A Global Perspective.

Diabetes Obes Metab. 2025-6-19

[6]
Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes.

Cochrane Database Syst Rev. 2016-6-7

[7]
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.

Respir Res. 2024-12-21

[8]
The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation.

Health Technol Assess. 2007-9

[9]
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease.

Cochrane Database Syst Rev. 2016-3-2

[10]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2017-12-22

本文引用的文献

[1]
Lipid metabolism in MASLD and MASH: From mechanism to the clinic.

JHEP Rep. 2024-8-9

[2]
Glycaemic control metrics and metabolic dysfunction-associated steatotic liver disease in children and adolescents with type 1 diabetes.

Diabetes Obes Metab. 2024-12

[3]
Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial.

Diseases. 2024-8-17

[4]
Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD.

Nat Commun. 2024-5-29

[5]
Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications.

Biomed Pharmacother. 2024-6

[6]
Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study.

Nutrients. 2024-5-2

[7]
Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease.

Cell Metab. 2024-5-7

[8]
Innate Immunity and MASLD.

Biomolecules. 2024-4-13

[9]
Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes.

J Endocrinol Invest. 2024-9

[10]
Double diabetes-when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition.

Cardiovasc Diabetol. 2024-2-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索